Introduction {#s1}
============

Preterm birth (PTB), defined as delivery prior to 37 weeks of gestation, is regarded as a global public health concern, since it is the leading cause of infant mortality worldwide ([@B3]). In comparison with infants born full-term, PTB infants are at a greater risk of multiple health problems, including neurological and long-term developmental disorders ([@B26]). Rates of PTB have fortunately declined over the last decade, occurring in approximately 12% of pregnancies in the U.S. ([@B30]). This decline is due, in part, to declines in the number of births to teens and young mothers. The annual economic cost related to PTB has been approximated at \$26 billion dollars in the U.S. and £939 million in the U.K. ([@B25]).

Many factors are thought to contribute to the increased PTB rate, including a higher mean maternal age, more frequent use of assisted reproductive technologies and a resulting increase in multiple gestations, and higher rates of preterm inductions and cesarean deliveries ([@B5]). Interestingly, since the prevalence of depression during pregnancy has increased from 8.3% to 12.7%, many studies have shown that antidepressant use during pregnancy increases the risk of PTB ([@B21]; [@B12]; [@B35]). Additionally, there exists emerging evidence that maternal depression during pregnancy is a risk factor for PTB ([@B12]; [@B35]). However, based on the existing literature, it is difficult to draw a unified conclusion regarding the association of antidepressant use during pregnancy and PTB, since the research differs in terms of the timing of antidepressant use during pregnancy, adjustment for potential confounding variables, inclusion of lifestyle factors, presence of comorbidities, and severity of the underlying psychiatric illness. The existing four published meta-analyses ([@B16]; [@B32]; [@B15]; [@B10]) had several limitations. Firstly, these meta-analyses consisted of both retrospective and prospective cohort studies, the former of which may have caused recall bias. Moreover, in these meta-analyses, there were no reports of depressed pregnant women in the study population ([@B16]; [@B32]; [@B15]), with the exception of one study ([@B10]) including eight original studies that examined the effect of selective serotonin reuptake inhibitor (SSRI) use on PTB in pregnant women with depression. Additionally, information regarding subgroup analyses stratified by geographic locations and whether adjustments were made for confounders \[e.g., maternal age, ethnicity, education, smoking, alcohol consumption, body mass index (BMI), and parity\] were not provided.

Therefore, in the present study, a meta-analysis of all available studies was conducted to quantitate the strength of the relationship between antidepressant use during pregnancy and PTB especially in depressed women.

Materials and Methods {#s2}
=====================

Search Strategy {#s2_1}
---------------

The PubMed, PsycINFO, and Embase databases were searched for related articles published before *June 30, 2019*. The search queries used are listed in [**Supplementary File 1**](#SM1){ref-type="supplementary-material"}. The articles were imported into the NoteExpress library for removal of the duplicates.

Study Selection {#s2_2}
---------------

Eligibility criteria were defined as: (1) articles available in English with the full text provided; (2) studies conducted in humans; (3) prospective cohort studies; (4) antidepressant use as the study exposure and PTB as the study outcome; (5) antidepressant use during pregnancy; (6) no psychotropic drug use in the control group; and (7) reported risk ratio or adequate data for the calculation of an effect size as a relative risk (RR) between antidepressant use and PTB.

Data Extraction {#s2_3}
---------------

The study quality of eligible articles was assessed by two reviewers (X-YM and X-RX), who subsequently extracted data from each selected article including the study design, sample size, data source, criteria for inclusion/exclusion, definition of exposure, definition of outcome, outcomes with risk estimates and 95% confidence intervals (CIs), and adjusted confounders. The two reviewers extracted data independently and any disagreements were resolved by discussion with a third reviewer (QC), when necessary.

For one study ([@B17]) that characterized neonates in the Swedish birth registry following maternal antidepressant use in late pregnancy, discussion among the three reviewers resulted in recalculation of the crude RR value according to the control group as the non-exposed population.

Risk of Bias Assessment {#s2_4}
-----------------------

The two reviewers independently performed a quality assessment using the Newcastle−Ottawa scale (NOS) ([@B38]) for cohort studies. The scale of this quality tool consists of three components for which a maximum of 9 points can be given: selection of study participant groups (max. 4 points); comparability of study groups (max. 2 points); and ascertainment of outcome (max. 3 points). Studies were considered to have a low risk of bias if they achieved a full rating in at least two of these categories ([@B29]).

Statistical Analysis {#s2_5}
--------------------

STATA, version 11.0 (StataCorp, College Station, TX) was used for all statistical analyses. The mean effect size approach was used to pool estimates, which has been applied in other studies ([@B27]; [@B13]). The effect size was weighted as per the study sample size. Estimates were pooled using the DerSimonian and Laird random-effects model to calculate the summarized RRs and 95% CI, as large inter-study heterogeneity was expected ([@B6]). For studies reporting the necessary data instead of providing the risk estimates directly, these data were used to calculate the crude RRs. The *I*^2^ value represents the percentage of total variation across studies due to heterogeneity rather than chance ([@B14]). Values of 25%, 50%, and 75% are regarded as representing low, moderate, and high heterogeneity ([@B14]). A two-tailed *P*-value \<0.05 was considered statistically significant. Potential publication bias was assessed using Begg\'s test ([@B2]).

If more than eight studies were available, potential sources of heterogeneity were explored by conducting subgroup analyses according to the following parameters: geographic location (Europe vs. North America or other regions) and adjustment for potential confounders (adjusted vs. unadjusted) including maternal age, ethnicity, maternal education, tobacco use, alcohol consumption, BMI during pregnancy, and parity. Heterogeneity between subgroups was evaluated by meta-regression analysis. To determine the influence of individual studies on each analysis of the estimated RR, sensitivity analysis was conducted that recalculated the pooled effect by omitting one study at a time. The population was divided into four groups: antidepressant use in the general pregnant female population, antidepressant use in pregnant women with depression, SSRI use in the general pregnant female population, and SSRI use in pregnant women with depression.

Results {#s3}
=======

Search Results {#s3_1}
--------------

A total of 2,278 potentially eligible articles were identified in PubMed, PsycINFO, and Embase. One additional study was added following a manual search of the reference lists. Following removal of 528 duplicate articles, the titles and abstracts were screened, and 1,577 irrelevant articles were removed. A total of 174 full-text articles were assessed for eligibility, and 23 (published between 2004 and 2019) were ultimately included in the present analysis. A flow diagram of study identification is shown in [**Figure 1**](#f1){ref-type="fig"}.

![Flowchart of the article selection process.](fphar-11-00659-g001){#f1}

All prospective cohort studies assessing antidepressant exposure during pregnancy were included. Eight studies ([@B4]; [@B23]; [@B11]; [@B28]; [@B37]; [@B19]; [@B31]) were conducted in Europe, 13 ([@B17]; [@B34]; [@B7]; [@B36]; [@B40]; [@B8]; [@B9]; [@B20]; [@B41]; [@B18]; [@B33]; [@B39]; [@B42]) in North America, 1 in Asia and southeast Europe ([@B1]), and 1 in Australia ([@B22]). The included studies all defined PTB as gestational weeks \<37, with the exception of one study, Malm H, 2015 ([@B24]), which classified PTB into two types \[late preterm (32−36 gestational weeks) and very preterm (\< 32 weeks) births\]. We did the analysis after combining them. Most studies evaluated the association between SSRI use and the risk of PTB (n = 12) ([@B17]; [@B34]; [@B36]; [@B40]; [@B27]; [@B11]; [@B41]; [@B16]; [@B1]; [@B24]; [@B37]; [@B42]); four studies evaluated the association between the use of all antidepressants and PTB ([@B36]; [@B8]; [@B28]; [@B19]); four studies evaluated the association between tricyclic antidepressant (TCA) ([@B17]), mirtazapine ([@B7]; [@B39]), and venlafaxine ([@B31]) use and PTB; three studies evaluated the association between the use of one or more antidepressants ([@B4]; [@B22]; [@B9]) and PTB; and one study evaluated the association between second-generation antipsychotics (SGAs) ([@B33]) (e.g., SSRIs, benzodiazepines, anticonvulsants, SNRIs, atypical antidepressants) and PTB. Eight studies recruited patients through the Teratology Information Service ([@B34]; [@B7]; [@B8]; [@B9]; [@B18]; [@B33]; [@B39]; [@B31]) and four studies recruited participants from the national birth registry ([@B17]; [@B37]; [@B19]). The characteristics of the included studies are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Characteristics of the studies included in the meta-analysis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                       Country                                  Year   Study type                        Data period            Definition of preterm              Exposure                           Sample size (preterm)   Adjusted confounders
  ---------------------------- ---------------------------------------- ------ --------------------------------- ---------------------- ---------------------------------- ---------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B31]                       UK                                       2019   UKTIS                             1995−2018              ---                                Venlafaxine                        1,274 (158)             Venlafaxine-exposed pregnancies by both calendar year and maternal age (each ±2 years) at UKTIS referral

  [@B19]                       Finnish                                  2019   National birth registry           2009−2015              \<37                               All ADs                            6263                    Age, cohabitation, smoking, education, body mass index, fertility treatments, previous pregnancies, and gestational diabetes mellitus

  [@B42]                       Connecticut and southern Massachusetts   2017   U.S. prospective cohort           2005−2009              \<37                               SRIs                               2,654 (225)             Age, race/ethnicity, educational level, and smoking, heavy drinking, and illicit drug use during pregnancy

  [@B37]                       Swedish                                  2016   National birth registry           2006−2009              \<259\                             SSRIs                              390,404                 Mother\'s education, mother\'s BMI, parity, mother\'s age at pregnancy, mother\'s previous psychiatric history, mother\'s smoking status at the first visit to maternal care
                                                                                                                                        days                                                                                          

  [@B39]                       Canada                                   2015   TIS                               1995−2011              \<37                               Mirtazapine                        581 (57)                Selected randomly, and cases and control subjects were matched by TIS center, year of TIS contact (± 2 years), maternal age (± 2 years), and gestational age at the time of call (± 4 weeks)

  [@B24]                       Finland                                  2015   National birth registry           1996−2010              Late preterm\                      SSRIs                              56,775 (2,449)          Gender and birth period (1996--2000, 2001--2005, and 2006--2010), maternal age at delivery, place of residence, marital status, parity, smoking, socioeconomic status, purchase of anxiolytics, sedative-hypnotics, or antiepileptic drugs, pre-pregnancy diabetes, and other chronic diseases
                                                                                                                                        (32−36 weeks)                                                                                 

  Very preterm (\< 32 weeks)   56,775 (359)                                                                                                                                                                                           

  [@B1]                        Konya and Istanbul                       2014   Turkish prospective cohort        ---                    20 \< weeks \< 37                  SSRIs                              89                      ---

  [@B33]                       Canada                                   2013   TIS                               2005−2009              \<37                               Second-generation antipsychotics   266 (17)                Age at conception (± 3 years) and pregnancy duration at the initial time of contact (± 2 weeks)

  [@B28]                       Norwegian                                2012   The MoBa study                    2000−2006              \<37                               All ADs                            62,347                  Level of depression, maternal age at delivery, education, parity, pre-pregnancy BMI, maternal asthma or cardiovascular disease, NSAID use, folic acid use, and smoking during pregnancy

  [@B41]                       Connecticut and southern Massachusetts   2012   U.S. prospective cohort           2005−2009              \<37                               SRIs                               2,654 (225)             Age, education, race, smoking, illicit drug use and pregnancy history, number of lifetime hospitalizations, age of depressive onset, number of prior depressive episodes, post-traumatic stress disorder, generalized anxiety disorder, panic disorder in pregnancy, and suicidal thoughts in pregnancy

  [@B11]                       Netherlands                              2012   The Generation R study            2002−2006              \<37                               SSRIs                              7,126 (365)             Maternal age at intake, gender of the child, maternal education, ethnicity, maternal smoking and drinking habits, body mass index, parity, and maternal benzodiazepine use

  [@B18]                       Canada                                   2012   TIS                               ---                    \<37                               Escitalopram                       425 (28)                Maternal age ±2 years, alcohol consumption and smoking, and gestational age at the time of call ±2 weeks

  [@B9]                        Canada                                   2011   TIS                               1992−2007              \<37                               All ADs                            178 (15)                Maternal age (± 2 years), smoking and alcohol use, time of call to Motherisk

  [@B20]                       Utah                                     2011   U.S. prospective cohort           2007.3−11              \<37                               SSRIs                              100                     ---

  [@B8]                        Canada                                   2010   TIS                               ---                    \< 37                              All ADs                            1,856 (132)             Maternal age (± 2 years), alcohol, tobacco, concurrent drug use

  [@B22]                       Australia                                2010   Clinic-based prospective cohort   2004−2005              \<37                               SSRIs/SNRIs/NaSSAs                 54 (5)                  ---

  [@B23]                       Denmark                                  2009   Aarhus birth prospective cohort   1989−2006              \<37                               SSRIs                              57,001 (2796)           Maternal age, body mass index, smoking, a previous pregnancy with prematurity, and parity

  [@B40]                       Cleveland and Pitts burgh                2009   U.S. prospective cohort           2000−2001, 2003−2007   Late preterm (≥34 to \<37 weeks)   SSRIs                              279 (24)                Maternal age and race

  Early preterm\                                                                                                                                                                                                                      
  (\< 34 weeks)                                                                                                                                                                                                                       

  [@B4]                        Swedish                                  2009   Omega study                       since 1996             20 \< weeks \< 37                  SSRIs/SSRI+SNRI                    2,631 (253)             Maternal age, race, years of education, marital status, smoking during pregnancy, preeclampsia, parity, and singleton/multiple pregnancy

  [@B36]                       Los Angeles                              2007   the University of California      2000−2005              ---                                All ADs                            90 (14)                 ---

  [@B7]                        Canada                                   2006   TIS                               2002−2005              \<37                               Mirtazapine                        208 (12)                Maternal age at the time of conception (± 2 years), gestational age at the first contact (± 2 weeks), tobacco use, alcohol consumption, and chronic conditions

  [@B34]                       Canada                                   2005   TIS                               1999-2002              \<37                               Citalopram                         264 (16)                Maternal age (± 2 years), gestational stage of pregnancy (± 2 weeks) at the time of recruitment

  [@B17]                       Swedish                                  2004   National birth registry           1995−2001              \<37                               Tricyclic                          563,656\                Year of birth, maternal age, parity, and maternal smoking in early pregnancy
                                                                                                                                                                                                              (28,743)                

  SSRIs                                                                                                                                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TIS, Teratogen Information Service; AD, antidepressant; SSRI, selective serotonin reuptake inhibitor; SRI, serotonin reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; NSAID, nonsteroidal anti-inflammatory drug; SNRI, serotonin--norepinephrine reuptake inhibitor; UKTIS, UK Teratology Information Service.

Bias Assessment {#s3_2}
---------------

Analysis of the included studies using Newcastle−Ottawa criteria indicated that 21 studies were at a low risk and two studies ([@B17]; [@B20]) were at a high risk of bias. All studies achieved a total score of 6−9 (median = 7) ([**Supplementary File 2**](#SM2){ref-type="supplementary-material"}).

Antidepressant Use in the General Pregnant Female Population {#s3_3}
------------------------------------------------------------

Sixteen studies ([@B17]; [@B34]; [@B23]; [@B4]; [@B40]; [@B8]; [@B9]; [@B20]; [@B28]; [@B18]; [@B33]; [@B39]; [@B24]; [@B42]; [@B31]; [@B19]) in the general pregnant female population were included for this analysis. The adjusted RR was 1.35 (95% CI 1.11−1.63, *I*^2^ = 75.8%, *P* \< 0.001, [**Figure 2**](#f2){ref-type="fig"}). A significantly increased risk of PTB was observed with antidepressant use in the general pregnant female population. Subgroup analysis of antidepressant use and the risk of PTB is shown in [**Table 2**](#T2){ref-type="table"}. In 10 North American studies, the adjusted RR was 1.78 (1.45−2.18). Following adjustment for maternal age, the RR was statistically significant \[1.28 (1.06−1.54)\]. If tobacco use and parity were not adjusted for, the RRs were statistically significant \[2.01 (1.35−2.98), 1.75 (1.45−2.11)\]. There was no evidence of publication bias in any of the studies.

![Meta-analysis of antidepressant use in pregnant women and the risk of preterm birth.](fphar-11-00659-g002){#f2}

###### 

Subgroup analysis of antidepressant use in the general pregnant women and the risk of preterm birth: results of the meta-analysis.

                               **Antidepressant**                                          
  ---------------------------- -------------------- -------------------- ------ ---------- ------
  Geographic location                                                                      0.01
   Europe                      6                    1.04 (0.84--1.23)    79.7   \< 0.001   
   Northern America            10                   1.78 (1.45--2.18)    5.3    0.39       
  Adjustment for confounders                                                               
  Maternal age                                                                             0.05
   Yes                         14                   1.28 (1.06--1.54)    74.9   \< 0.001   
   No                          2                    4.60 (0.99--21.19)   60.8   0.11       
  Ethnicity                                                                                0.39
   Yes                         4                    1.59 (1.22--2.06)    0.0    0.52       
   No                          12                   1.27 (1.02--1.57)    79.5   \< 0.001   
  Maternal education                                                                       0.92
   Yes                         5                    1.36 (1.11--1.68)    0.0    0.90       
   No                          11                   1.36 (1.07--1.72)    80.0   \< 0.001   
  Tobacco use                                                                              0.05
   Yes                         6                    1.19 (0.97--1.45)    79.4   \< 0.001   
   No                          10                   2.01 (1.35--2.98)    30.7   0.18       
  Alcohol consumption                                                                      0.22
   Yes                         4                    1.73 (1.34--2.24)    0.0    0.70       
   No                          12                   1.24 (1.01--1.52)    75.5   \< 0.001   
  Pregnancy BMI                                                                            0.55
   Yes                         2                    1.93 (1.26--2.95)    0.0    0.48       
   No                          14                   1.31 (1.07--1.59)    75.7   \< 0.001   
  Parity                                                                                   0.01
   Yes                         5                    1.03 (0.83--1.28)    81.8   \< 0.001   
   No                          11                   1.75 (1.45--2.11)    0.0    0.46       

BMI, body mass index; CI, confidence interval; RR, relative risk.

\*P for heterogeneity within each subgroup.

\*\*P for heterogeneity between subgroups with meta-regression analysis.

Antidepressant Use in Pregnant Women With Depression {#s3_4}
----------------------------------------------------

Seven studies ([@B7]; [@B36]; [@B22]; [@B41]; [@B11]; [@B1]; [@B37]) in the pregnant women with depression were included for this analysis. The adjusted RR was 1.58 (95% CI 1.23−2.04, *I*^2^ = 9.7%, *P* = 0.365, [**Figure 3**](#f3){ref-type="fig"}). A significantly increased risk of PTB was observed when the analysis was restricted to pregnant women with depression. Subgroup analysis of antidepressant use in pregnant women with depression and the risk of PTB was shown in [**Table 3**](#T3){ref-type="table"}. In two European studies, the adjusted RR was 1.51 (95% CI 1.20−1.91). Following adjustment for maternal age, ethnicity, maternal education, tobacco use, BMI during pregnancy, and parity, the adjusted RRs were statistically significant: 1.62 (1.20−2.18), 1.89 (1.09−3.28), 1.46 (1.32−1.62), 1.62 (1.20−2.18), 1.51 (1.20−1.91), and 1.46 (1.32−1.62), respectively. There was no evidence of publication bias in any of the studies.

![Meta-analysis of antidepressant use in pregnant women with depression and the risk of preterm birth.](fphar-11-00659-g003){#f3}

###### 

Subgroup analysis of antidepressant use in pregnant women with depression and risk of preterm birth: results of meta-analyses.

                               Antidepressant use                                      
  ---------------------------- -------------------- -------------------- ------ ------ ------
  Geographic location                                                                  0.75
   Europe                      2                    1.51 (1.20--1.91)    17.6   0.27   
   Northern America            3                    1.28 (0.12--14.07)   0.0    0.40   
   Others                      2                    2.17 (1.05--4.52)    58.8   0.12   
  Adjustment for confounders                                                           
  Maternal age                                                                         0.99
   Yes                         4                    1.62 (1.20--2.18)    21.1   0.28   
   No                          3                    1.64 (0.38--7.01)    29.0   0.25   
  Ethnicity                                                                            0.48
   Yes                         2                    1.89 (1.09--3.28)    0.0    0.55   
   No                          5                    1.78 (0.94--3.39)    26.8   0.24   
  Maternal education                                                                   0.32
   Yes                         3                    1.46 (1.32--1.62)    0.0    0.54   
   No                          4                    2.42 (0.78--7.49)    27.2   0.25   
  Tobacco use                                                                          0.99
   Yes                         4                    1.62 (1.20--2.18)    21.1   0.28   
   No                          3                    1.64 (0.38--7.01)    29.0   0.25   
  Alcohol drinking                                                                     0.16
   Yes                         2                    2.50 (1.32--4.73)    2.3    0.31   
   No                          5                    1.45 (1.31--1.61)    0.0    0.58   
  Pregnancy BMI                                                                        0.54
   Yes                         2                    1.51 (1.20--1.91)    17.6   0.27   
   No                          5                    2.00 (0.94--4.28)    15.3   0.32   
  Parity                                                                               0.32
   Yes                         3                    1.46 (1.32--1.62)    0.0    0.54   
   No                          4                    2.42 (0.78--7.49)    27.2   0.25   

BMI, body mass index; CI, confidence interval; RR, relative risk.

\*P for heterogeneity within each subgroup.

\*\*P for heterogeneity between subgroups with meta-regression analysis.

SSRI Use in the General Pregnant Female Population {#s3_5}
--------------------------------------------------

Nine studies ([@B23]; [@B40]; [@B20]; [@B11]; [@B41]; [@B1]; [@B24]; [@B37]; [@B42]) in the general pregnant female population were included for this analysis. The adjusted RR was 1.25 (95% CI 1.01−1.57, *I*^2^ = 85.6%, *P* \< 0.001, [**Figure 4**](#f4){ref-type="fig"}). The heterogeneity of the studies was high and no significantly increased risk of PTB was observed for SSRI use in the general pregnant female population. Subgroup analysis of SSRI use and risk of PTB is shown in [**Table 4**](#T4){ref-type="table"}. In four North American studies, the adjusted RR was 1.91 (1.27−2.86). Following adjustment for ethnicity, maternal education, alcohol consumption, and BMI during pregnancy, the adjusted RRs were statistically significant: 1.85 (1.33−2.57), 1.47 (1.33−1.62), 1.70 (1.19−2.44), and 1.63 (1.27−2.09), respectively. If parity was not adjusted, the RR was statistically significant \[2.24 (1.03−4.84)\]. There was no evidence of publication bias in any of the studies.

![Meta-analysis of selective serotonin reuptake inhibitor use in pregnant women and the risk of preterm birth.](fphar-11-00659-g004){#f4}

###### 

Subgroup analysis of selective serotonin reuptake inhibitor use and risk of preterm birth in infants: results of meta-analyses.

                               SSRI use                                           
  ---------------------------- ---------- -------------------- ------- ---------- ------
  Geographic location                                                             0.22
   Europe                      4          1.07 (0.82--1.39)    92.30   \< 0.001   
   Northern America            4          1.91 (1.27--2.86)    33.6    0.17       
   Others                      1          0.39 (0.05--3.16)    --      --         
  Adjustment for confounders                                                      
  Maternal age                                                                    0.34
   Yes                         7          1.22 (0.97--1.52)    86.4    \< 0.001   
   No                          2          2.27 (0.08--63.58)   83.9    0.01       
  Ethnicity                                                                       0.13
   Yes                         3          1.85 (1.33--2.57)    0.0     0.45       
   No                          6          1.11 (0.86--1.42)    89.4    \< 0.001   
  Maternal education                                                              0.45
   Yes                         3          1.47 (1.33--1.62)    0.0     0.52       
   No                          6          1.14 (0.88--1.47)    79.7    \< 0.001   
  Tobacco use                                                                     0.10
   Yes                         6          1.16 (0.92--1.45)    89.0    \< 0.001   
   No                          3          2.60 (0.86--7.84)    50.9    0.09       
  Alcohol drinking                                                                0.45
   Yes                         2          1.70 (1.19--2.44)    0.0     0.44       
   No                          7          1.18 (0.92--1.51)    86.9    \< 0.001   
  Pregnancy BMI                                                                   0.26
   Yes                         3          1.63 (1.27--2.09)    77.5    0.21       
   No                          6          1.09 (0.85--1.40)    0.4     \< 0.001   
  Parity                                                                          0.12
   Yes                         5          1.12 (0.88--1.43)    89.9    \< 0.001   
   No                          4          2.24 (1.03--4.84)    52.0    0.06       

BMI, body mass index; CI, confidence interval; RR, relative risk; SSRI, selective serotonin reuptake inhibitor.

\*P for heterogeneity within each subgroup.

\*\*P for heterogeneity between subgroups with meta-regression analysis.

SSRI Use in Pregnant Women With Depression {#s3_6}
------------------------------------------

Only four studies ([@B11]; [@B41]; [@B1]; [@B37]) in the pregnant women with depression were included for this analysis. The adjusted RR was 1.46 (95% CI 1.32−1.61, *I*^2^ = 0.0%, *P* = 0.432, [**Figure 5**](#f5){ref-type="fig"}). A significantly increased risk of PTB was observed with SSRI use in pregnant women with depression. There was no evidence of publication bias in any of the studies.

![Meta-analysis of selective serotonin reuptake inhibitor use in pregnant women with depression and the risk of preterm birth.](fphar-11-00659-g005){#f5}

Discussion {#s4}
==========

Main Findings {#s4_1}
-------------

To the best of our knowledge, this is the first meta-analysis of the impact of antidepressant use during pregnancy on PTB in depressed women. Our study focused not only on depressed pregnant women but also on the general pregnant female population, with 23 prospective cohort studies finally being selected. It was found that the risk of PTB was increased in depressed women treated with SSRIs during pregnancy. Similar results were observed in women with depression and in the general pregnant female population who used antidepressants during pregnancy. There was no significantly increased risk of PTB observed with SSRI use in the general pregnant female population.

The focus of the present study was to explore the association between maternal use of antidepressants in depressed women during pregnancy and risk of PTB. Subgroup analysis shows that even though the use of antidepressants in the general pregnant female population significantly increased the risk of PTB, the heterogeneity was high, which may be due to the differences in population sources. There was a statistically significant difference in the European cohort study but not in the North American cohort study, which may be one of the sources of heterogeneity. Another reason for the high heterogeneity may be that there were confounding factors that influenced the conclusion. For this reason, a meta-regression analysis was conducted; when maternal age, tobacco use, and parity were defined, there was a statistically significant difference in the meta-regression, indicating that these may be confounding factors.

To further explore whether the heterogeneity originated from different drug types, subgroup analysis of SSRI use in the general pregnant female population was conducted, and it was found that the heterogeneity was elevated. A possible reason could be differences in the sources of the population. Firstly, according to geographic location, studies were divided into European, North American, and others; the *P* values were 0.27, 0.40, and 0.12, respectively, and the meta-regression was not statistically significant. Subsequently, the data were adjusted for certain confounding factors such as maternal age, ethnicity, maternal education, tobacco use, and alcohol consumption; however, the results were not ideal. Finally, a subgroup analysis of SSRI use in pregnant women with depression was performed, and it was found that the heterogeneity was 0%; therefore, a possible source of the high heterogeneity was not stipulating depression in the study population. However, there have only been four studies to date, and the present study suggests that future studies may be inclined to stipulate depression in the study population and to consider the effects of SSRIs or other antidepressants on preterm PTB, which is of great clinical significance.

Comparison With the Existing Literature {#s4_2}
---------------------------------------

Currently, there exist four meta-analyses of the effects of antidepressant use on PTB (nearly 6 years) ([@B15]; [@B16]; [@B32]; [@B10]). The results of the present study among studies in general pregnant women were consistent with these published meta-analyses. However, these original cohort studies were both retrospective and prospective, which could have caused recall bias. Moreover, there was no stipulation of depression in the study population, with the exception of one study ([@B10]) including eight original studies, which focused on the effect of SSRIs on PTB in pregnant women with depression. Following adjustment for confounders, the incidence of PTB was significantly higher in pregnant women treated with SSRIs as compared with that in the controls \[adjusted odds ratios (aOR) 1.24, 95% CI 1.09−1.41\]. Our included studies were all prospective cohort studies with high quality evidence and high credibility. [@B16] included 41 original studies, and the pooled adjusted odds ratio was 1.53 (1.40−1.66) for antidepressant use at any time during pregnancy and 1.96 (1.62−2.38) for use during the third trimester; however, confounding factors were not adjusted for. In another study by [@B32], 13 original studies providing 14 estimates of the association between antidepressant use and PTB resulted in a pooled OR of 1.55 (95% CI, 1.38−1.74; *P* \< 0.001); after limiting the population to depressed pregnant women, the OR was 1.79 (0.77−4.14). Moreover, a study by [@B15] included 28 original studies and the meta-analysis showed that antidepressant use in pregnancy was significantly associated with PTB (RR: 1.69, 95% CI: 1.52−1.88).

Strengths and Limitations {#s4_3}
-------------------------

The present study describes a meta-analysis of 23 prospective cohort studies investigating the risk of PTB in women taking antidepressants during pregnancy, with additional analyses associated with a diagnosis of depression. The main strength is that it is a large meta-analysis including a large number of prospective cohort studies. Furthermore, to-date, evidence regarding associations between the use of antidepressant in depressed women and risk of PTB is limited. To the best of our knowledge, the present study is the first meta-analysis to investigate the associations between maternal antidepressant use in depressed women and the risk of PTB.

Nevertheless, this study has several limitations, which should be considered when interpreting its findings. First, due to the limited number of included studies, the present study did not account for trimester exposure and either for duration of exposure in the analysis. Both factors may significantly modify the association between maternal use of antidepressant during pregnancy and PTB. The number of studies related to specific antidepressants are small for specific drugs (i.e., SSRIs) and did not allow for investigations into the dose-response. Second, heterogeneity was high among studies focusing on the associations between maternal antidepressant use in the general pregnant women and the risk of PTB. Our subgroup analysis suggested that the high heterogeneity might be attributed to differences in study locations and diagnosing of depression.

Conclusions {#s5}
===========

The results of this meta-analysis highlights the association between maternal use of antidepressant during pregnancy and the risk of PTB. Health care providers and pregnant women must weigh the risk-benefit potential of these drugs when making decisions about whether to treat with antidepressant during pregnancy.
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